Overview
Nutrition supplement maker's Q1 net sales rose 7.8% yr/yr, adjusted EPS beat analyst expectations
Q1 adjusted EBITDA exceeded company guidance
Company completed $1.45 bln debt refinancing and acquired Bioniq's personalized nutrition business
Outlook
Herbalife raises full-year 2026 constant currency net sales and adjusted EBITDA guidance midpoints
Company sees Q2 2026 net sales up 1.5% to 5.5% YoY, adjusted EBITDA $150 mln–$170 mln
Herbalife expects full-year 2026 net sales up 1.5% to 5.5% YoY, adjusted EBITDA $675 mln–$705 mln
Result Drivers
REGIONAL SALES MIX - Strong growth in Asia Pacific and Latin America drove overall sales increase, while North America and China saw declines
PRICING AND INVENTORY - Gross margin decline was mainly due to input cost inflation and unfavorable sales mix, partially offset by pricing benefits and lower inventory write-downs
PERSONALIZATION STRATEGY - Co cited ongoing strategic focus on personalized nutrition, including Bioniq acquisition and new packaging rollout
Company press release: ID:nBw71CdjSa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
$0.64
$0.57 (3 Analysts)
Q1 EPS
$0.57
Q1 Net Income
$61.90 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the food processing peer group is "buy"
Wall Street's median 12-month price target for Herbalife Ltd is $19.00, about 16.9% above its May 5 closing price of $16.26
The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 7 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)